A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. [PDF]
PLoS ONE, 2013 BACKGROUND: Prescribers, payors and healthcare decision-makers are increasingly examining the value of treatments. This study aims at analyzing economic value of chronic hepatitis B (CHB) treatment options, which are available in Korea.
Jun Yong Park +8 more
doaj +1 more source
Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection-General and Special Populations. [PDF]
Aliment Pharmacol TherCurrent first‐line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD.
Mak LY, Hu TH, Yap DYH.
europepmc +2 more sources
[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]
Clinical Management Issues, 2015 BACKGROUND AND AIM: The current treatment of chronic hepatitis B infection (CHBV) has achieved several step-ups thanks to the introduction of the new-generation nucleos(t)ide analogs.
Fabio Tarsetti +4 more
doaj +1 more source
Molecules, 2023 Bentysrepinine (Y101) is a novel phenylalanine dipeptide for the treatment of hepatitis B virus. Renal excretion played an important role in the elimination of Y101 and its metabolites, M8 and M9, in healthy Chinese subjects, although the molecular ...
Aijie Zhang +13 more
doaj +1 more source
Beni-Suef University Journal of Basic and Applied Sciences, 2022 Background A meta-analysis was made to assess the impact of entecavir comparison with tenofovir disoproxil fumarate as nucleos(t)ide analogue on hepatic cellular carcinoma (HCC). The study had subjects with chronic hepatitis B virus (HBV).
Sara M. Tony +3 more
doaj +1 more source
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance [PDF]
, 2011 We report a case of an immunocompromised patient affected by chronic hepatitis B virus (HBV) with high basal HBV viremia (>8 log(10) IU/ml) who failed an entecavir regimen, despite the absence of primary or secondary drug resistance mutations.
Andreoni, M +8 more
core +1 more source
A Rare Side Effect of Entecavir: Hepatomegaly and Steatosis
Viral Hepatitis Journal, 2017 Hepatomegaly and steatosis are rare but potentially fatal side-effects of nucleoside analogues. Here, we present the case of development of hepatomegaly and steatosis in a 53-year-old male who had been treated with entecavir for five years. There were no
Tayibe BAL +2 more
doaj +1 more source
Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial. [PDF]
, 2017 Background: Telbivudine has been suggested to induce hepatitis B surface antigen (HBsAg) decline to the similar degree as pegylated interferon. We aimed to investigate whether telbivudine could further decrease HBsAg titer in patients who maintain ...
���������
core +1 more source
Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma
Gut and Liver, 2016 Background/AimsAntiviral therapy is a key component in the management of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. However, whether the potent drug entecavir is more effective than a less potent drug, such as lamivudine, in
Jung Hee Kim +9 more
doaj +1 more source
Viruses, 2021 Hepatitis B virus (HBV) chronic infection causes progressive liver damage, although about 20% of patients develop extrahepatic manifestations such as cryoglobulinemic vasculitis (CV). Clinical manifestations range from mild to moderate (purpura, asthenia,
Cesare Mazzaro +11 more
doaj +1 more source